U.S. HHS/BARDA Deal History & Licensing Activity
U.S. HHS/BARDA is a life sciences. Over the past three years, U.S. HHS/BARDA has been involved in 7 licensing and acquisition transactions, with a primary focus on mRNA (8 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
mRNA
Focus Area
Infectious Disease
U.S. HHS/BARDA Recent Deal Activity
Licensing, acquisition, and partnership transactions involving U.S. HHS/BARDA in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| mRNA pandemic influenza vaccine | BARDA | mRNA | Preclinical | collaboration | Jul 2025 |
U.S. HHS/BARDA Pipeline Focus
Therapeutic areas and modalities where U.S. HHS/BARDA is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches U.S. HHS/BARDA's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About U.S. HHS/BARDA Licensing & Deal Activity
U.S. HHS/BARDA is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, U.S. HHS/BARDA ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for U.S. HHS/BARDA include Infectious Disease (8 deals and trials). In terms of modality, U.S. HHS/BARDA has shown particular interest in mrna.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for U.S. HHS/BARDA and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against U.S. HHS/BARDA's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.